Pompe Disease - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

Pompe disease market size in 2026 is estimated at USD 2.04 billion, growing from 2025 value of USD 1.91 billion with 2031 projections showing USD 2.86 billion, growing at 6.98% CAGR over 2026-2031. This report is Segmented by Route of Administration (Oral, Parenteral), by Therapy Type (Enzyme Replacement Therapy (ERT), Combination Therapy, Other Therapies), by Disease Onset Type (Infantile-Onset Pompe Disease (IOPD), Late-Onset Pompe Disease (LOPD)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and More), by Geography (North America, Europe, Asia-Pacific, and More).

Global Pompe Disease Market Trends and Insights

Launch of Novel Second-Generation ERTs

Second-generation enzymes such as cipaglucosidase alfa, launched in combination with miglustat, improve mannose-6-phosphate tagging and cellular uptake, delivering greater glycogen clearance in skeletal muscle and demonstrating superior patient-reported outcomes versus legacy alglucosidase alfa. Europe’s early designation of the regimen as preferred therapy for adults with late-onset disease signals traction beyond the United States, while Amicus projects more than USD 1 billion in cumulative revenue by 2028. Market enthusiasm is reinforced by regulatory flexibility under orphan-drug frameworks that shorten review cycles and extend exclusivity, encouraging other sponsors to prioritise enhanced ERT constructs.

Expanding Newborn Screening Mandates

Genomics-first screening programmes in China, Japan, and several US states detect Pompe disease at markedly higher rates than enzyme-activity assays, with Chinese pilots reporting overall lysosomal prevalence of 1 in 1,512 births. Earlier identification drives pre-symptomatic treatment, especially for infantile-onset cases where rapid cardiac and respiratory decline can be prevented. Governments are embedding Pompe panels into national screening catalogues, extending reimbursement and stimulating sustained uptake that underpins long-run prescription volume growth.

High Therapy Cost

Annual per-patient spending of EUR 483,907 in Germany positions Pompe as the costliest lysosomal disorder, with 98.5% attributable to drug acquisition. Although orphan-drug policy supports premium pricing, payers now demand hard outcomes data before granting full reimbursement, prolonging negotiations and delaying broad launch roll-outs, particularly for combination and gene-therapy entrants.

Other drivers and restraints analyzed in the detailed report include:

• mRNA-Based ERT Platforms in Clinical Trials
• Gene-Therapy Funding Surge
• Delayed Diagnosis & Low Awareness

Segment Analysis

Parenteral products accounted for 90.88% of the Pompe disease market in 2025, resulting in a market size of USD 1.74 billion and a 6.25% CAGR, driven by the advancement of improved enzyme constructs into the clinic. Intravenous delivery benefits from decades of clinician familiarity, mature specialty-pharmacy logistics, and proven clinical benefit in stabilising respiratory and ambulatory function. Avalglucosidase alfa exemplifies formulation innovation, incorporating bis-phosphorylated mannose-6-phosphate tags that enhance muscle uptake and facilitate longer infusion intervals. Temperature-controlled distribution advances keep product wastage below 1% and maintain an on-time delivery rate of 98%, further solidifying the parenteral model.

Oral administration remains a nascent but strategically important approach. Maze Therapeutics’ MZE-001, an oral glycogen-synthase inhibitor, underpins Sanofi’s USD 750 million acquisition and Shionogi’s USD 150 million licensing pact, reflecting the conviction that a convenient daily pill can complement or even displace biweekly infusions. If Phase II data confirm glycogen-reduction biomarkers, the Pompe disease industry could see a bifurcated treatment algorithm, wherein patients transition from parenteral ERT to oral substrate-reduction maintenance, altering the revenue mix and logistical demands.

Enzyme replacement therapy generated 89.75% of 2025 revenue, equal to a Pompe disease market size of USD 1.71 billion, but its share is projected to decline modestly as combination regimens scale. Clinicians continue to rely on alglucosidase alfa and avalglucosidase alfa due to extensive long-term safety data and reimbursement familiarity. However, the FDA approval of cipaglucosidase alfa plus miglustat heralds a paradigm shift: Amicus reported 90% year-over-year revenue growth in Q1 2025 as treatment-experienced patients switched to the combination following improved six-minute-walk test scores.

Gene and mRNA therapies populate the “other” category and may compress the ERT window of dominance. A single-administration AAV vector or once-monthly mRNA injection could reshape adherence patterns, particularly for younger cohorts. Developers must nonetheless clear manufacturing and immunogenicity hurdles before large-scale commercialisation.

Complete Report Scope:

• By Route of Administration
  • Oral
  • Parenteral
• By Therapy Type
  • Enzyme Replacement Therapy (ERT)
  • Combination Therapy
  • Other Therapies
• By Disease Onset Type
  • Infantile-Onset Pompe Disease (IOPD)
  • Late-Onset Pompe Disease (LOPD)
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America anchored 46.20% of 2025 sales, equivalent to USD 0.88 billion, reflecting robust payer coverage, active newborn screening across all US states, and early-adopter behaviour among neuromuscular specialists. The region also captures the majority of ongoing phase III gene-therapy trials, supported by deep capital markets and an experienced contract-manufacturing ecosystem. Policy shifts such as Inflation Reduction Act price negotiations inject uncertainty but are unlikely to undermine high clinical value assessments for life-threatening rare diseases.

Europe constitutes the second-largest regional block, characterised by a harmonised regulatory pathway through the European Medicines Agency yet fragmented reimbursement decision-making at the member-state level. Western European nations generally fund Pompe ERT within three months of marketing authorisation, whereas many Central and Eastern European markets lag by more than two years, creating intra-regional access disparities. Industrial commitments such as Roche’s EUR 90 million gene-therapy site in Germany and UCB’s EUR 200 million enzyme facility in Belgium reflect growing confidence that Europe will remain a profitable launch region despite rising health-technology-assessment scrutiny.

Asia-Pacific registers the fastest trajectory at 9.02% CAGR. China’s mandatory genomic newborn screening yielded incidence data that immediately expanded the diagnosed population and triggered policy moves to subsidise ERT. Japan’s Pharmaceuticals and Medical Devices Agency maintains an expedited 9-month median review cycle for orphan drugs, with seven years of exclusivity, incentivising sponsors to submit global dossiers early. Meanwhile, Australia and South Korea have added avalglucosidase alfa to national reimbursement schedules, signalling broader regional integration of next-generation therapies. Supply-chain investments, including local fill-finish capacity, mitigate import-related delays and lower landed costs, fostering sustainable volume growth.

List of Companies Covered in this Report:

• Sanofi
• Amicus Therapeutics
• Astellas Pharma / Audentes
• Asklepios BioPharmaceutical (AskBio)
• Genethon
• Orchard Therapeutics
• Shionogi & Co., Ltd.
• Beijing GeneCradle Technology Co., Ltd.
• Maze Therapeutics, Inc.
• Exerkine Corporation

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support